[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342348-105":59,"doc-detail-342348-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","increased-risk-of-subsequent-primary-lung-cancer-among-female-hormone-related-cancer-patients-a-meta-analysis-based-on-over-four-million-cases","Increased risk of subsequent primary lung cancer among female hormone-related cancer patients - A meta-analysis based on over four million cases","","Female hormone-related cancer (FHRC) patients—encompassing breast, endometrial, cervical, and ovarian cancers—may face a higher probability of later lung cancer, and this meta-analysis quantified that risk versus the general population. Searches across PubMed, Web of Science, EMBASE, Cochrane Library, and CNKI up to May 11, 2022 used standardized incidence ratios (SIRs) with 95% confidence intervals, with subgroup analyses by follow-up duration and tumor type. Results showed a significant overall increase (SIR=1.61, 95% CI 1.48–1.76, P\u003C0.001).",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/increased-risk-of-subsequent-primary-lung-cancer-among-female-hormone-related-cancer-patients-a-meta-analysis-based-on-over-four-million-cases/342348/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/increased-risk-of-subsequent-primary-lung-cancer-among-female-hormone-related-cancer-patients-a-meta-analysis-based-on-over-four-million-cases/342348.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does this meta-analysis address?","Question",{"text":112,"@type":113},"It evaluates whether patients with female hormone-related cancers (breast, endometrial, cervical, and ovarian) have an increased risk of developing subsequent primary lung cancer compared with the general population.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the studies selected and analyzed?",{"text":117,"@type":113},"Databases including PubMed, Web of Science, EMBASE, Cochrane Library, and CNKI were searched up to May 11, 2022, and standardized incidence ratios (SIRs) with 95% confidence intervals were used, with subgroup analyses by follow-up time and tumor type.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings about risk magnitude and time trend?",{"text":121,"@type":113},"Across 58 retrospective cohort studies with 4,360,723 FHRC participants, FHRC patients had a significantly higher risk of subsequent primary lung cancer (SIR=1.61, P\u003C0.001). The risk increased with longer survival/follow-up duration in the subgroup analyses.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342348,1790094377,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Increased risk of subsequent primary lung cancer among female hormone-related cancer patients: A meta-analysis based on over four million cases  \nYan Wang1, Wenpeng Song2, Haoyu Wang3, Guonian Zhu3,4, Yangqian Li3,4, Zhoufeng Wang3,5, Weimin Li3,4,5, Guowei Che1,2  \n1Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;  \n2Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;  \n3Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;  \n4Institute of Respiratory Health, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;  \n5Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Networks, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.  \nAbstract  \nBackground: The incidence rate of lung cancer in women has significantly increased over the past decade, and previous evidence has indicated a significant relationship between the elevated levels of sex hormones and the risk of lung cancer. Therefore, we hypothesized that female hormone-related cancer (FHRC) patients, including breast, endometrial, cervical, and ovarian cancer patients, may experience a higher risk of developing subsequent lung cancer. This meta-analysis aimed to identify the risk of lung cancer among FHRC patients compared to the general population.  \nMethods: The PubMed, Web of Science, EMBASE, Cochrane Library, and CNKI databases were searched up to May 11, 2022. Standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) were used to identify the risk of subsequent lung cancer after FHRC. Subgroup analyses based on the follow-up time and tumor type were also conducted.  \nResults: A total of 58 retrospective cohort studies involving 4,360,723 FHRC participants were included. The pooled results demonstrated that FHRC patients had a significantly increased risk of developing subsequent primary lung cancer (SIR = 1.61, 95% CI: 1.48–1.76, P \u003C0.001) . Subgroup analysis revealed an obvious trend of increasing lung cancer risk over time (SIRs for \u003C5 years, ≥5 years, ≥ 10 years, ≥20 years, and ≥30 years after FHRC: 1.32, 1.59, 1.57, 1.68, and 1.95, respectively) . In addition, subgroup analysis stratified by tumor type indicated an increased risk of developing subsequent lung cancer after breast (SIR = 1.25, P \u003C0.001), endometrial (SIR = 1.40, P = 0.019), cervical (SIR = 2.56, P \u003C0.001), and ovarian cancer (SIR = 1.50, P = 0.010) .  \nConclusion: FHRC patients are more likely to develop lung cancer than the general population. Furthermore, the increased risk of subsequent primary lung cancer is more obvious with a longer survival time and is observed in all types of hormone-related cancer. Registration: International Platform of Registered Systematic Review and Meta-analysis Protocols: No. INPLASY202270044;  \n[https://inplasy.com/](https://inplasy.com/)  \nKeywords: Female hormone-related cancer; Risk; Subsequent primary lung cancer; Meta-analysis  \nIntroduction  \nAccording to the latest cancer data, lung cancer is the second most common tumor and remains the leading cause of tumor-related death among women in the United States. [1] Moreover, the sex proportion and age distribution of lung cancer patients have changed significantly in the past decade, with obviously more young female patients than before. [1,2] In addition, breast cancer has become the most common cancer in the United States with a rising incidence, and the incidence rates of other female  \n\n| Access this article online |  |\n| --- | --- |\n| Quick Response Code: | Website:\u003Cbr>[www.cmj.org](www.cmj.org) |\n|  | DOI:\u003Cbr>10.1097/CM9.0000000000003132 |\n\ntumors, including uterine endometrial, uterine cervical, and ovarian cancers, have also been relatively high over the past few decades. [1,3,4] Overall, these four cancers are the leading causes of cancer burden in w","cbCaiibVUC4lIm6h","https://ap.wps.com/l/cbCaiibVUC4lIm6h","pdf",3134031,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What question does this meta-analysis address?\",\"answer\":\"It evaluates whether patients with female hormone-related cancers (breast, endometrial, cervical, and ovarian) have an increased risk of developing subsequent primary lung cancer compared with the general population.\"},{\"question\":\"How were the studies selected and analyzed?\",\"answer\":\"Databases including PubMed, Web of Science, EMBASE, Cochrane Library, and CNKI were searched up to May 11, 2022, and standardized incidence ratios (SIRs) with 95% confidence intervals were used, with subgroup analyses by follow-up time and tumor type.\"},{\"question\":\"What were the key findings about risk magnitude and time trend?\",\"answer\":\"Across 58 retrospective cohort studies with 4,360,723 FHRC participants, FHRC patients had a significantly higher risk of subsequent primary lung cancer (SIR=1.61, P\\u003c0.001). The risk increased with longer survival/follow-up duration in the subgroup analyses.\"}]","Increased risk of subsequent primary lung cancer among female hormone-related cancer patients - A meta-analysis based on over four million cases | PDF",1790046251,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2462121ade75ef5e3f8cf892d57fdfbc.webp",983,1324,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96397886524361330e68f0c86b89c00e.webp",982,1323,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88be886ca4f25af9d7b9a7517ebeddef.webp",981,1321,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/100f426550b7f06a9d1a73efa4f44f79.webp",980,1320]